Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658902 | 0.85 | MEN1 (0.47) | IDO1AGXTKDM4ERIPK1MEN1 | |
| SCHEMBL18356065 | 0.83 | P2RX7 (0.41) | IDO1AGXTGAAKDM4EMEN1 | |
| SCHEMBL17141730 | 0.81 | MEN1 (0.49) | GAAKDM4EMEN1PKMKMT2A | |
| SCHEMBL18392591 | 0.81 | ADRA2B (0.51) | IDO1AGXTGAAKDM4EMEN1 | |
| SCHEMBL13900832 | 0.81 | P2RX7 (0.43) | MEN1PKMKMT2AP2RX7ALDH1A1 | |
| SCHEMBL7920951 | 0.80 | IDO1 (0.41) | IDO1AGXTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL9074382 | 0.80 | RIPK1 (0.43) | IDO1AGXTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL17788629 | 0.79 | SLC6A4 (0.41) | GAAKDM4EMEN1PKMKMT2A | |
| SCHEMBL2095744 | 0.78 | SLC6A4 (0.49) | IDO1AGXTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL13959189 | 0.78 | CA2 (0.49) | GAASMN1; SMN2PKMALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20090088436-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-7482345-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2009-01-27 | — | — | US | disclosed |
| US-7482345-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2009-01-27 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070129372-A1 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-20070129372-A1 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-6194461-B1 | USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0945426-A1 | NITRONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088436-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | IDO1 314/4885AGXT 2314/4885GAA 1757/4885 |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | IDO1 2108/4885AGXT 695/4885GAA 1055/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | IDO1 783/4885AGXT 4458/4885GAA 3888/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | IDO1 2108/4885AGXT 695/4885GAA 1055/4885 |
| US-20070129372-A1 | P38 kinase inhibiting agents | MAPK1, MAPK8, MAPK7 | IDO1 314/4885AGXT 2314/4885GAA 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.